Literature DB >> 31497784

Antimicrobial use and misuse at the end of life: a retrospective analysis of a treatment escalation/limitation plan.

Adrian Wilder-Smith1, Thomas Gillespie2, D Robin Taylor3,1.   

Abstract

BACKGROUND: Antimicrobial treatment is common at end of life. A treatment escalation/limitation plan (TELP) offers the opportunity to avoid non-beneficial treatment in critically ill patients. Our aim was to evaluate antimicrobial prescribing in terminally ill patients, and assess whether it was modified using a TELP.
METHODS: Appropriateness of antimicrobial treatment was audited using a priori criteria in 94 consecutive hospital deaths. Prescribing in patients whose death was expected/unexpected, and who had a TELP with/without a 'ceiling' for antimicrobials, were compared.
RESULTS: Twenty three of 94 patients (24.5%) were receiving antimicrobials at time of death. This was not influenced by evidence of infection or whether death was expected. The use of a TELP (n = 81) with an antimicrobial 'ceiling' (28 with, 53 without) was associated with a significant reduction in antimicrobials administered (28.6% vs 81.1%; p < 0.0005).
CONCLUSIONS: Many complex factors contribute to antimicrobial misuse at end of life. An appropriately constructed TELP reduces inappropriate prescribing.

Entities:  

Keywords:  advance care plan; antibiotic; antimicrobial; end-of-life care; terminal care; treatment escalation

Mesh:

Substances:

Year:  2019        PMID: 31497784     DOI: 10.4997/JRCPE.2019.304

Source DB:  PubMed          Journal:  J R Coll Physicians Edinb        ISSN: 1478-2715


  1 in total

1.  Association of Physician Orders for Life-Sustaining Treatment With Inpatient Antimicrobial Use at End of Life in Patients With Cancer.

Authors:  Olivia S Kates; Elizabeth M Krantz; Juhye Lee; John Klaassen; Jessica Morris; Irina Mezheritsky; Ania Sweet; Frank Tverdek; Elizabeth T Loggers; Steven A Pergam; Catherine Liu
Journal:  Open Forum Infect Dis       Date:  2021-08-02       Impact factor: 4.423

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.